Age-related macular degeneration (AMD) is a progressive eye disease and a leading cause of blindness, affecting 13 million people in the U.S. alone. It impacts the retina of the eye, in an area called the macula where detailed central vision occurs. There is a strong, well-understood correlation between AMD and dark adaptation, which measures how quickly an individual recovers vision when going from bright light to darkness.
The AdaptDx® has the potential to be the first practical diagnostic for early detection and tracking of AMD. It is being developed to provide doctors with an easy-to-use, functional test that will allow them to intervene at the earliest possible time, preventing vision loss and improving quality of life.
Preserving Vision Before It's Too Late
Gregory R. Jackson, PhD, Associate Professor of Ophthalmology at Penn State College of Medicine, discusses the promise of the AdaptDx as a test for age-related macular degeneration (AMD), a disorder that affects millions of people, and often goes undiagnosed for years.